Christian Klein

Christian Klein is the inventor of CrossMab technology and has been one of the most prolific bispecific antibody developers in the pharmaceutical industry. At Roche, he led development of ~25 CrossMab-based bispecific antibodies advancing to clinical trials, including two FDA-approved products: faricimab (Vabysmo, 2022) for retinal diseases and glofitamab (Columvi, 2023) for lymphoma. With 220+ publications and 240+ patent families, Klein joined Curie.Bio as Chief Scientist Officer in October 2024 after two decades at Roche. His CrossMab technology solves the light chain mispairing problem in bispecific antibody production through domain crossover, enabling efficient manufacturing of clinically validated therapeutics.

Christian Klein博士是CrossMab技术的发明者，是制药行业最多产的双特异性抗体开发者之一。在罗氏，他领导开发了约25种基于CrossMab的双特异性抗体进入临床试验，包括两个FDA批准产品：faricimab（Vabysmo，2022年）用于视网膜疾病，glofitamab（Columvi，2023年）用于淋巴瘤。凭借220多篇出版物和240多个专利族，Klein在罗氏工作二十年后于2024年10月加入Curie.Bio担任首席科学官。他的CrossMab技术通过结构域交换解决了双特异性抗体生产中的轻链错配问题。